Skip to main content
OpenTrials
Completed

NCT Number: NCT07315139

Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients

This study aimed to determine the impact of Pentoxifylline on inflammatory biomarkers and the progression of chronic kidney disease in non-diabetic patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pentoxifylline Chronic Disease Chronic Kidney Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Inflammatory Markers Kidney Diseases Male Urogenital Diseases Non-Diabetic Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ain Shams University

Cairo, 11591, Egypt

About this study

Chronic kidney disease (CKD) is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals.

The diagnosis of CKD is established by laboratory testing, most often by estimating glomerular filtration rate (GFR) from a filtration marker, such as serum creatinine or cystatin C, using various formulas, or by testing urine for albumin or protein (or both).

Pentoxifylline (PTX), a synthetic dimethylxanthine derivative used initially to treat intermittent claudication in patients with peripheral arterial disease due to its hemorheological effects, has been shown to have potent antioxidant, anti-inflammatory, antidiabetic, anti-cellular-damage, and antifibrotic effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ˃ 18 years old.
  • Both sexes.
  • Patients with chronic kidney disease (CKD) stages G3, G4.
  • Patients with proteinuria < 1 g.

Exclusion criteria

  • Patients who are terminally ill.
  • Patients with Diabetes mellitus.
  • Patients with proteinuria > 1 g.
  • Patients with a history of hemodialysis.
  • Patients with active infection or hospitalized.
  • Patients with recent cerebral and /or retinal Hemorrhage.
  • Patients taking warfarin or theophylline-containing drugs.
  • women who are taking oral contraceptives, pregnant, or lactating
  • Patients with a history of adverse reactions to Pentoxifylline.
  • Patients with polycystic kidney disease.
  • Patients with obstructive uropathy.

Treatment and study plan

Angiotensin-converting enzyme inhibitors (Ramipril)

Drug

Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.

Pentoxifylline

Drug

Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.

Primary outcomes

  1. Levels of inflammatory marker

    Time frame: 3 months post-procedure

    Levels of inflammatory marker was recorded.

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Effect of Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jan 2, 2026
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.